Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

morning brief

- PMLiVE

First efficacy data for GSK/Prosensa’s muscular dystrophy candidate positive

Ups ante in race against Sarepta Therapeutics to market first Duchenne muscular dystrophy drug

- PMLiVE

GSK partners with Singapore research agency on emerging markets

Will work with A*STAR’s Institute of Chemical and Engineering to research reformulated medicines

- PMLiVE

BMS and Vertex partner on oral hepatitis treatment

Will investigate combination of daclatasvir and VX-135

- PMLiVE

GSK’s four-strain flu vaccine approved in Germany and UK

Will be sold as Influsplit Tetra in Germany and Fluarix Tetra in the UK

- PMLiVE

FDA delays GlaxoSmithKline’s pandemic flu vaccine

More time needed due to "administrative" issue

- PMLiVE

Merck Serono signs diabetes partnership with BMS in China

Will co-promote Glucophage (metformin) formulations

- PMLiVE

Mixed reaction to Novo Nordisk obesity trial

Analyst says Victoza only has a modest ability to reduce weight in people with diabetes

- PMLiVE

GSK’s Ellen Strahlman joins med tech firm BD

Will serve as the US company's chief medical officer

- PMLiVE

GSK submits albiglutide for European approval

If approved the diabetes drug will be launched as Eperzan

- PMLiVE

Novo’s Lantus rival Tresiba hits European markets

Company says its insulin degludec is a more flexible alternative to Sanofi's product

- PMLiVE

UK study supports earlier narcolepsy finding with GSK’s Pandemrix

Flu vaccine linked to sleeping disorder

- PMLiVE

NICE recommends BMS-Pfizer’s Eliquis to prevent stroke

Joins Xarelto and Pradaxa anticoagulants as potential warfarin replacement

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links